Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Eur Rev Med Pharmacol Sci. 2023 May;27(10):4735-4751. doi: 10.26355/eurrev_202305_32485.
Epilepsy, a neurodegenerative disorder, continues to throw challenges in the therapeutic management. The current study sought to ascertain if the therapeutic interactions between piracetam and diethylstilbestrol may prevent grand-mal seizures in rats.
Piracetam (PIR; 10 and 20 mg/kg) and diethylstilbestrol (DES; 10 and 20 mg/kg) alone as a low-dose combination were administered to rats for 14 days. The electroshock (MES; 180 mA, 220 V for 0.20 s) was delivered via auricular electrodes on the last day of treatment and rats were monitored for convulsive behavior. To elucidate the mechanism, hippocampal mechanistic target of rapamycin (mTOR) and interleukin (IL)-1β, IL-6 and tumor necrotic factor-alpha (TNF-α) levels were quantified. Hippocampal histopathology was conducted to study the neuroprotective effect of drug/s. In vitro studies and in silico studies were conducted in parallel.
To our surprise, the low dose of the combination regimen of PIR (10 mg/kg) and DES (10 mg/kg) unfolded synergistic anti-seizure potential, with brimming neuroprotective properties. The mechanism could be related to a significant reduction in the levels of hippocampal mTOR and proinflammatory cytokines. The docking scores revealed higher affinities for phosphatidylinositol 3-kinase (PI3K) in co-bound complex, and when docking DES first, while better affinities for protein kinase B (Akt) were revealed when docking PIR first (both drugs bind cooperatively as well). This indicated that the entire PI3K/Akt/mTOR signaling pathway is intercepted by the said combination. In addition, the % of cell viability of HEK-293 cells [pre-exposed to pentylenetetrazol (PTZ)] was increased by 327.29% compared to PTZ-treated cells (toxic control; 85.16%).
We are the first to report the promising efficacy of the combination (PIR 10 mg/kg + DES 10 mg/kg) to restrain seizures and epileptogenic changes induced by electroshock by a novel mechanism involving inhibiting the PI3K/Akt/mTOR signaling.
癫痫是一种神经退行性疾病,在治疗管理方面仍然存在挑战。本研究旨在确定吡拉西坦和己烯雌酚之间的治疗相互作用是否可以预防大鼠大发作性癫痫发作。
吡拉西坦(PIR;10 和 20mg/kg)和己烯雌酚(DES;10 和 20mg/kg)单独作为低剂量组合在 14 天内给予大鼠。在最后一天的治疗中,通过耳电极给予电休克(MES;180mA,220V,0.20s),并监测大鼠的惊厥行为。为了阐明机制,定量测定海马机械靶蛋白雷帕霉素(mTOR)和白细胞介素(IL)-1β、IL-6 和肿瘤坏死因子-α(TNF-α)水平。进行海马组织病理学检查以研究药物的神经保护作用。同时进行体外研究和计算研究。
令我们惊讶的是,PIR(10mg/kg)和 DES(10mg/kg)的低剂量组合方案展现出协同抗惊厥潜力,并具有显著的神经保护特性。该机制可能与海马 mTOR 和促炎细胞因子水平的显著降低有关。对接评分显示,在共同结合复合物中,与磷酸肌醇 3-激酶(PI3K)的亲和力更高,当首先对接 DES 时,而当首先对接 PIR 时,与蛋白激酶 B(Akt)的亲和力更高(两种药物也协同结合)。这表明整个 PI3K/Akt/mTOR 信号通路被所述组合阻断。此外,与仅用戊四氮(PTZ)处理的细胞(毒性对照;85.16%)相比,预先暴露于戊四氮的 HEK-293 细胞的细胞活力百分比增加了 327.29%。
我们是第一个报告该组合(PIR 10mg/kg+DES 10mg/kg)通过新的机制抑制 PI3K/Akt/mTOR 信号来抑制电休克诱导的癫痫发作和癫痫样变化的有希望的疗效的人,该机制涉及抑制 PI3K/Akt/mTOR 信号。